|
|
VACCINATION
TEST KIT
|
28
Vials $95
|
| Code |
Vaccine |
Type |
Vaccination
Requirements |
Possible
Long Term Effects |
| VA1 |
B.C.G.
(Tuberculosis) |
live
attenuated |
In UK
at age 12-13 |
TB, ME |
| VA2 |
Cholera |
killed
organisms |
vaccination
only recommended if travelling to cholera areas across remote borders,
especially overland. |
severe
allergic reactions to vaccine, nerve damage, mental problems |
| VA3 |
D.P.T.
(Diphtheria, Whooping Cough, Tetanus) |
toxoids
of diphtheria & tetanus; inactivated pertussis |
introduced
in 1957 in UK, by 1969 over 80% of children vaccinated |
sudden
infant death syndrome, brain damage, asthma |
|
|
|
|
|
|
|
|
recommended
regime is 4 times before age 6 and then age 14-16 years old, and then
every 10 years afterwards |
|
| VA4 |
Diphtheria |
inactivated
bacterial toxins |
introduced
in 1930’s, now mainly given as DPT |
|
| VA5 |
Diphtheria
/ Tetanus |
inactivated
bacterial toxins |
now mainly
given as DPT |
|
| VA6 |
Encephalitis |
inactivated |
travel
vaccination for Far East, Indian subcontinent, South East Asia |
|
| VA7 |
Hepatitis
A |
|
travel
vaccination |
|
| VA8 |
Hepatitis
B |
genetic
engineering (yeast or plasma derived) |
In New
Zealand vaccination of babies introduced in 1988 and abandoned in early
1990’s following evidence of immune suppression; routinely offered to
infants in US, but not in UK; compulsory in Italy |
ME, arthritis,
kidney disease, nerve inflammation, severe skin eruptions, eye problems |
| VA9 |
HIB (Bacterial
Meningitis caused by Haemophilus Influenzae type b) |
|
introduced
in US in 1985 and UK in 1992; given routinely in US at 18 months |
|
| VA10 |
Influenza
(various strains) 2 |
killed
organisms |
|
encephalitis,
neuritis, optic neuritis, vasulitis and joint problems, reversible paralysis,
myelopathy, exacerbate asthma |
| VA11 |
Measles |
live
attenuated |
first
introduced in UK in 1968 and in US in 1957; banned in UK in August 1999
to force parents to use MMR |
|
| VA12 |
Meningitis |
polysaccaride |
Saudi
Arabia requires immunisation for those going on pilgrimage to Mecca |
|
| VA13 |
MMR (Measles,
Mumps and Rubella) |
live
attenuated |
first
introduced in UK in 1988 and in US in 1975 |
autism,
Crohn’s disease, seizures |
| VA14 |
MR (Measles
and Rubella) |
live
attenuated |
|
|
| VA15 |
Pertussis
(Whooping Cough) |
killed
organisms |
first
available in 1912; commonly available mid 1950’s; now mainly given as
DPT; |
brain
damage, asthma |
|
|
|
|
|
|
|
|
compensation
for vaccine damage introduced in UK in 1978 |
|
| VA16 |
Pneumovax |
polysaccaride |
given
to elderly people to prevent pneumonia a few years ago |
|
| VA17 |
Polio
(Sabin) |
attenuated
live given orally |
in use
since mid 1960’s, prior to that the Salk polio vaccine was used |
weight
gain, Guillain-Barre syndrome, ME |
| VA18 |
Polio
(Salk) |
killed
organisms given intramuscularly |
polio
vaccine first introduced in 1952/53 in US and 1956 in UK; the Sabin polio
vaccine used in America and England since 1960’s; Finland, Sweden and
Netherlands use this polio vaccine |
|
| VA19 |
Rabies |
killed
organisms |
travel
vaccination for those exposed to an unusual risk of infection e.g. taking
long journeys in the bush |
|
| VA20 |
Rubella
(German Measles) |
live |
rubella
during earlier pregnancy can result in damage to unborn child (congenital
Rubella Syndrome) |
arthritis,
polneuralgia, chronic fatigue syndrome |
| VA21 |
Smallpox |
|
introduced
in England in 1840 and made compulsory in 1853; it is now believed that
smallpox has been eradicated so immunisation is no longer required; USA
vaccination programme stopped in 1972, re-introduced for selected categories
of people in 2003 |
|
| VA22 |
TAB (Paratyphoid) |
killed
organisms |
|
|
| VA23 |
Tetanus |
inactivated
bacterial toxins |
now mainly
given as DPT |
|
| VA24 |
Typhoid |
killed
organisms |
|
|
| VA25 |
Yellow
Fever |
live
attenuated |
|
|
| VA26 |
Meningitis
C |
|
First
used in UK in clinical trials in 1994; vaccination programme started in
1999 in UK, and from 2000 in Eire |
|
| VA27 |
5-In-1
Vaccine{whooping cough, diphtheria, bacterial meningitis, tetanus and
polio} |
|
introduced
into the UK in October 2004 |
|
| VA28 |
Pneumococcal/Prevenar
|
from
Streptococcus pneumoniae |
protective
against meningitis, septicaemia, ear infections and pneumonia. Introduced
2000 in US, 2002 in Canada, 2005 in Australia and 2006 in UK; given to
children under 5 |
|
